UBS has raised its price target for Sartorius Stedim Biotech to 215 euros after the company's third-quarter results were released.
The Swiss bank has maintained its "Neutral" rating on the biotechnology firm, with analyst Matthew Weston stating that the adjustment is due to higher valuations in the industry.
The updated price target reflects a positive outlook for Sartorius Stedim Biotech in a favorable market environment.
The report, published on October 22, 2024, discusses the ongoing trends in biotechnology valuations that may impact investor sentiment.